172 related articles for article (PubMed ID: 30710182)
1. ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma.
Jin W; Xu HX; Yu XJ; Liu L
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):571-572. PubMed ID: 30710182
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Zhang SR; Li H; Wang WQ; Liu L; Yu XJ
Ann Surg Oncol; 2018 Dec; 25(13):3994-3995. PubMed ID: 30315385
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: Potential Role of Circulating Biomarkers in Resected Pancreatic Adenocarcinoma.
White MG; Tzeng CD
Ann Surg Oncol; 2021 Aug; 28(8):4623-4624. PubMed ID: 33507452
[No Abstract] [Full Text] [Related]
4. Tumor-Infiltrating NETs Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Jin W; Xu HX; Zhang SR; Li H; Wang WQ; Gao HL; Wu CT; Xu JZ; Qi ZH; Li S; Ni QX; Liu L; Yu XJ
Ann Surg Oncol; 2019 Feb; 26(2):635-643. PubMed ID: 30374923
[TBL] [Abstract][Full Text] [Related]
5. ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma.
Kubota K; Shimizu A; Soejima Y
Ann Surg Oncol; 2022 Feb; 29(2):1449-1450. PubMed ID: 34618246
[No Abstract] [Full Text] [Related]
6. ASO Author Reflections: Relationship Between Sarcopenia, Patient Prognosis, and Tumor-Infiltrating T Cells in Pancreatic Ductal Adenocarcinoma.
Masuda S; Yamakawa K; Masuda A
Ann Surg Oncol; 2023 Sep; 30(9):5788-5789. PubMed ID: 37166741
[No Abstract] [Full Text] [Related]
7. ASO Author Reflections: Improving Identification of Intraductal Papillary Mucinous Neoplasm Patients at Risk-Current Status and the Role of IPMN Molecular Biomarkers.
Maker AV
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):818-819. PubMed ID: 30311163
[No Abstract] [Full Text] [Related]
8. ASO Author Reflections: Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single Institutional Study.
Miyata T; Hayashi H; Baba H
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):903-904. PubMed ID: 32840745
[No Abstract] [Full Text] [Related]
9. ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma.
Newhook TE; Tzeng CD
Ann Surg Oncol; 2021 Mar; 28(3):1570-1571. PubMed ID: 32880772
[No Abstract] [Full Text] [Related]
10. ASO Author Reflections: Accurate Evaluation of Malignant Potential in Pancreatic Ductal Adenocarcinoma Using DUPAN-2 Level.
Sumiyoshi T; Uemura K
Ann Surg Oncol; 2024 Jul; 31(7):4697. PubMed ID: 38739237
[No Abstract] [Full Text] [Related]
11. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma?
Groot VP; Wolfgang CL; He J
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):806-807. PubMed ID: 30298312
[No Abstract] [Full Text] [Related]
12. ASO Author Reflections: Postoperative Carbohydrate Antigen 19-9 Levels Become a Reliable Biomarker for Establishing Intensity-Stratified Adjuvant Treatments in Pancreatic Ductal Adenocarcinoma.
Ariake K; Okada T; Tsuchiya H; Kuboki D; Maemura K; Ichikawa H; Tachibana T; Akazawa N; Abe T; Kakita T; Oikawa M; Tsuchiya T
Ann Surg Oncol; 2024 Jan; 31(1):548-549. PubMed ID: 37907696
[No Abstract] [Full Text] [Related]
13. ASO Author Reflections: Proposal of Tumor Size as an Index for Biologic Factor of Resectability Status of Pancreatic Ductal Adenocarcinoma.
Miyata Y; Kishi Y
Ann Surg Oncol; 2023 Dec; 30(13):8644-8645. PubMed ID: 37689609
[No Abstract] [Full Text] [Related]
14. ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients.
Chattopadhyay A; Wu CH; Tien YW; Lu TP
Ann Surg Oncol; 2022 Mar; 29(3):1616-1617. PubMed ID: 34802101
[No Abstract] [Full Text] [Related]
15. ASO Author Reflections: Real Prevalence of Occult Cancer Cells in Peritoneal Lavage in Patients with Pancreatic Ductal Adenocarcinoma.
Suenaga M; Fujii T
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):893-894. PubMed ID: 32812111
[No Abstract] [Full Text] [Related]
16. ASO Author Reflections: Preceding Systemic Chemotherapy Might Provide Better Prognosis for Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology.
Ariake K; Mizuma M; Motoi F; Unno M
Ann Surg Oncol; 2021 Oct; 28(11):6255-6256. PubMed ID: 33634387
[No Abstract] [Full Text] [Related]
17. ASO Author Reflections: Health Disparities in Pancreatic Cancer.
Lutfi W; Hogg ME
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):824-825. PubMed ID: 30377920
[No Abstract] [Full Text] [Related]
18. ASO Author Reflections: The Naples Prognostic Score Predicts Long-Term Survival in Patients with Resected Pancreatic Cancer.
Nakagawa N; Yamada S; Kodera Y
Ann Surg Oncol; 2020 Mar; 27(3):896-897. PubMed ID: 31848821
[No Abstract] [Full Text] [Related]
19. ASO Author Reflections: Role of SOX9 Transcription Factor in Pancreatic Neoplasms.
Turner K; Gnerlich JL
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):567-568. PubMed ID: 30680476
[No Abstract] [Full Text] [Related]
20. ASO Author Reflections: Positive Status of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: Are They Candidates for Radical Resection?
Kawakatsu S; Shimizu Y; Matsuo K; Hosoda W
Ann Surg Oncol; 2022 Sep; 29(9):5984-5985. PubMed ID: 35441307
[No Abstract] [Full Text] [Related]
[Next] [New Search]
